Options covered in this guide

DesireWolverineNAD+ · 500 mgNAD+ · 1,000 mgSelank / SemaxARA-290AOD-9604MOTS-cSS-31SelankSemaxDSIPThymosin Alpha-1KisspeptinMelanotan IISLU-PP-3325-Amino-1MQL-Carnitine

Desire

Desire contains PT-141, also known as bremelanotide, and relates to melanocortin and sexual-desire signaling research.

Formulation & presentation

PT-141, 10 mg total, in a 5 mL vial.

This 10 mg / 5 mL presentation should not be equated with an approved branded medicine containing bremelanotide.

Wolverine

Wolverine combines BPC-157 and TB-500 in a two-component formulation. These compounds are studied in tissue-repair research.

Formulation & presentation

BPC-157 5 mg + TB-500 5 mg.

Container volume requires confirmation. Clinical benefits of this combination are not established.

NAD+ · 500 mg

NAD+ is nicotinamide adenine dinucleotide, a coenzyme involved in cellular energy and metabolism. This presentation contains 500 mg in 10 mL.

Formulation & presentation

NAD+, 500 mg total, in a 10 mL presentation.

The 500 mg and 1,000 mg formulations have different total contents. Confirm the exact presentation when comparing them.

NAD+ · 1,000 mg

NAD+ is nicotinamide adenine dinucleotide, a coenzyme involved in cellular energy and metabolism. This presentation contains 1,000 mg in 10 mL.

Formulation & presentation

NAD+, 1,000 mg total, in a 10 mL presentation.

The 500 mg and 1,000 mg formulations have different total contents. Confirm the exact presentation when comparing them.

Selank / Semax

This two-component formulation combines Selank and Semax, peptides discussed in neurological research.

Formulation & presentation

Selank 5 mg + Semax 5 mg, in a 5 mL vial.

This combination is distinct from standalone Selank and Semax. Clinical benefits of the blend are not established.

ARA-290

ARA-290, also known as cibinetide, is an erythropoietin-derived peptide studied in tissue-protection and nerve-related research.

Formulation & presentation

ARA-290 (cibinetide), 10 mg total, at 2 mg/mL in a 5 mL vial.

Research terminology is not a treatment recommendation. Suitability should be discussed individually.

AOD-9604

AOD-9604 is a fragment related to human growth hormone, discussed in metabolic research.

Formulation & presentation

AOD-9604, 5 mg total, in a 5 mL vial.

Metabolic research does not establish a weight-loss indication for this presentation.

MOTS-c

MOTS-c is a mitochondrial-derived peptide studied in cellular-energy and metabolic research.

Formulation & presentation

MOTS-c, 10 mg total, in a 5 mL presentation.

Research topics and formulation strength do not establish clinical effectiveness.

SS-31

SS-31, also known as elamipretide, is a mitochondria-targeting peptide. This presentation contains 10 mg.

Formulation & presentation

SS-31, 10 mg total.

This presentation should not be equated with a separately authorized branded medicine containing the same compound.

Selank

Selank is a peptide discussed in neurological research. Its standalone profile is separate from the Selank / Semax blend.

Formulation & presentation

Selank, 10 mg total, in a 5 mL presentation.

Standalone Selank and the Selank / Semax blend have different component amounts and are not interchangeable.

Semax

Semax is a synthetic peptide related to an ACTH sequence, discussed in neurological research. It also appears in the Selank / Semax blend.

Formulation & presentation

Semax, 10 mg total, in a 5 mL presentation.

Confirm the exact concentration and formulation before comparing presentations. No administration calculations are provided here.

DSIP

DSIP stands for Delta Sleep-Inducing Peptide. Exact product identity requires confirmation before relying on this profile.

Formulation & presentation

10 mg. Exact product identity requires confirmation.

Exact product identity and manufacturer specifications require confirmation.

Thymosin Alpha-1

Thymosin Alpha-1 is a peptide modeled after a thymus-associated hormone, discussed in immune-signaling research.

Formulation & presentation

Thymosin Alpha-1, 10 mg total, in a 5 mL vial.

Immune-signaling research does not establish a clinical benefit for this preparation.

Kisspeptin

Kisspeptin is discussed in reproductive-hormone signaling research. The exact peptide form requires confirmation.

Formulation & presentation

Kisspeptin, 10 mg total, in a 5 mL vial; exact form is not specified.

Different Kisspeptin forms exist. Confirm the exact sequence rather than assuming a form such as Kisspeptin-10.

Melanotan II

Melanotan II is an alpha-MSH-related synthetic peptide discussed in pigmentation research.

Formulation & presentation

Melanotan II, 10 mg total, in a 5 mL vial.

Pigmentation research does not establish protection from UV exposure.

SLU-PP-332

SLU-PP-332 is an investigational compound discussed in cellular-energy and metabolic research; it is not a peptide.

Formulation & presentation

SLU-PP-332, 10 mg total.

Metabolic research does not establish this compound as a substitute for exercise or a treatment.

5-Amino-1MQ

5-Amino-1MQ is an investigational compound associated with NNMT inhibition. It is not classified here as a peptide.

Formulation & presentation

5-Amino-1MQ, 10 mg total.

Its inclusion alongside peptides does not define its molecular class or establish a clinical use. A complete technical specification is needed for the exact material.

L-Carnitine

L-Carnitine is an amino-acid-derived compound involved in fatty-acid transport and discussed in cellular and metabolic research.

Formulation & presentation

500 mg/mL. Container volume requires confirmation.

A concentration alone does not specify how much material a container holds. No total vial content is assigned to this entry without a stated volume.

Understanding the formulation

For Desire, review the active compound or compounds, concentration, presentation and proposed purpose. A blend name does not establish that every ingredient has the same evidence or clinical role. Ask the clinician to distinguish research findings from established uses and explain the evidence relevant to your particular goal.

What to review in your consultation

Your discussion of Desire should connect the profile information above to your individual health history. Bring your medication and supplement list, allergies, previous treatment experience and any current symptoms. Ask what evaluation or testing is needed and whether another approach would better address your concern.

Making an informed decision

Review the exact product, its regulatory status and the evidence for the intended use. Concentration and container size describe a presentation; they are not a personal dosing plan. The clinician explains potential adverse effects, relevant interactions and limitations before any treatment decision. An investigational profile is not a recommendation or an offer of an approved treatment.

Monitoring & next steps

If an appropriate treatment is agreed, the plan should describe how progress and tolerability will be reviewed, when follow-up takes place and whom to contact with concerns. Discuss realistic expectations and how decisions about continuing or changing the plan will be made. Personal medical guidance comes from the clinician who assesses you, rather than from a product description.

Educational information. Individual suitability and medical decisions require a consultation with a qualified clinician.